NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Under such a scenario as you propose, shouldn’t then the patients who were in the screening pipeline have also been informed of this “low likelihood” of answering that same hypothetical question of whether their PFS would be extended by entering the main arm of the trial? I would think that those patients would be entitled to know such a detail before entering the main arm of the trial. In fact, I’ll go a step further and say all patients should be told that if it were the case.

And yet, no such warning was given them.

Additionally, if OS is an independently measured endpoint as Dr Bosch claims it is, then if there was still a high likelihood that answering the more important question of whether OS would be extended was still in play, I’d think putting a halt on enrollment in the trial would be, well, an almost naughty thing to do.